0:00
0:34 Introducing Dr. Alicia RodriguePla
1:51 What is EGPA?
4:44 Pathogenesis
8:17 Epidemiology
9:15 Patient case study
10:16 Symptoms
11:31 Phases of EGPA
12:57 ANCA vs ANCA +
13:57 Diagnosis
16:50 Differentiating features.
18:36 Treatment
19:28 Treatment timeline.
20:45 Treatment: Refractory disease.
21:00 ACR / VF Guidelines.
23:26 Antiil5/il5r biologic therapies
25:53 Antiil5 therapies in EGPA
26 :43 Mepolizumab (I)
27 :52 Benralizumab (I)
29:33 Phase 2 reslizumab study for EGPA
29:47 Take home messages

31:23 Q: Many of us have no eosinophils b/c of pred, Nucala, etc. but still have flares, or
need additional meds to manage the epga. What can cause flares in EGPA when the
EOS are 0?
34:30 Q: What does DAH mean?
36:28 Q: What is the youngest patient the doctor has treated for EGPA?
37:23 Q: Could you tell us again how the drug Mepolizumab could help patients?
39:39 Q: Have you experience with EGPA patients successfully maintaining remission
off all treatments?
41:15 Q: Are vaccines such as flu, covid, and shingles recommended?
41:53 Q: Do you know the timeline of approval for the use of bevacizumab to treat
EGPA? What was the dosing frequency in the study was it 30 mg every 4
weeks?
43:03 Q: Is it normal having a lot of surgeries in the sinuses? Every year? And
inflammation in other organs?
44:06 Q: What percentage of patients develop antibodies to Benralizumab over time?
44:54 Q: Rituximab was not listed on the IL5 inhibitor slides. In addition to B cell
interaction, does Rituximab also inhibit IL5?
45:39 Q: How common is neuropathy?
47:23 Q: How is asthma treated when someone has EGPA?
48:12 Q: Thoughts about diet and vasculitis?
50:15 Q: Why is tavneos only for ANCA positive? We cannot use it right?
52:37 Q: Who should be on my medical team? Should I have a pulmonologist with
EGPA?

Overview of EGPA
Recorded June 2024

In this webinar, Alicia RodriguezPla, MD, PhD, MPH, a rheumatologist at Sierra Pacific Arthritis and Rheumatology Centers in Fresno, California, helps you to understand the symptoms, diagnosis, and available treatment strategies for EGPA. She also review spotential complications from the disease, as well as what’s on the horizon—current research and ongoing clinical studies.